Categories
Uncategorized

Desmoid tumor

2023

Benign fibromatous soft tissue sarcomatous tumors with minimal metastatic potential that tend to invade locally and often recur after surgical resection.

Aggressive fibromatosis.

Incidence 2-4 cases per million people per year.

Annual incidence is estimated to be 1000 patients in the United States, and the prevalence may be higher.

.03-0.1% of all solid tumors.

Most commonly arises between the ages of 15-and 60 years.

Typically affects young adults in their 20s and 30s, but can occur in children, adolescents, and older adults.

Most cases are sporadic, greater than 90%, and harbor CTNBB2 mutations.

A minority of tumors are associated with germline APC mutations and Gardner’s syndrome.

Female predominance of 2-3 fold.

More common among women and most frequently occurs in the limb girdle.

Estrogenic influence demonstrated by association with pregnancy.

Extremely rare for a patients to present with multifocal disease.

Tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.

Up to 20% of patients report spontaneous regression.

Incidence is about 1000 times in patients with familial adenomatous polyposis in which adenomatous polyposis gene (APC) is mutated.

Familial adenomatous polyposis associated desmoid tumor is more frequently abdominal tumor, especially in the Gardner variant which is characterized by intestinal polyposis, osteomas, fibrmoas, and epidermal inclusion cysts.

Desmoid- type fibromatosis develops in approximately 5-30% of patients with FAP usually in the mesentery.

Classified as intra or extra-abdominal.

Can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs.

Common primary sites include the abdominal wall, mesentery, and neurovascular bundle of the extremities.


They do not metastasize and pose low risk of death except in Gardner’s syndrome, but they can cause substantial complications.

Presentation ranges from a symptomatic to severe pain, swelling, deformity, loss of range of motion, bowel obstruction or perforation, or compromise of vital organs.

Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression free survival and induced durable responses: The progression free survival rate was 81% at two years vs, 36% in the placebo group (Gounder MM).

Pazopanib have similar activities as sorafenib.

Histological a poorly circumscribed proliferation of myofibroblast-like cells with variable collagen deposition.

Has been associated with trauma, pregnancy, and oral contraceptive use.

Trauma is a common inciting agent.

Surgery may sometimes promotes growth of desmoid tumors.

The natural history is highly variable.

Extra-abdominal tumors are usually sporadic and treated with surgery with or without surgery.

Surgery can be avoided using conservative approach 85% of patients with dermoid tumors of abdominal wall and in more than 90% of those in other sites.

Radiation may also be effective for primary therapy for extra-abdominal tumor.

From 4-38% of patients with FAP develop desmoid tumors.

Median time of recurrence 23 months with 90% of recurrences by 5 years.

Overall survival rates 90% at 20 years.

Do not dedifferentiate to a high grade malignancy or metastasize.

Rate of local recurrence dependent upon type of resection performed, with a wide local excision offering a recurrence rate of 50% and a recurrence rate of 90% with incomplete resections.

Recurrence rate higher for women and patients over the age of 30 years.

Recurrence rates of 39-79%.

Overall 10 year actuarial recurrence rate 33%.

There is no standard of care.

Watching/ wait strategy is increasingly advocated.

Active surveillance has occurred because the behavior of tumors is unpredictable and spontaneous growth arrest and regression can occur.

Optimum therapy requires pain control.

A period of observation of 12-24 months of surveillance is advised prior to beginning active therapy.

In about half of patients initial progression is followed by tumor stabilization which subsequently can be followed by regression.

In the other half of patients surveilled, persistent disease progression or worsening of symptoms requires active therapy.

Wide local excision with negative margins is the treatment of choice.

Risk of local recurrence rate is greater than 40%.

Unresectable disease should be treated with radiation.

Systemic treatment options include hormonal blockade, cytotoxic chemotherapy, tyrosine kinase inhibitors with a response rate varying between zero and 40%.

Endocrine therapy with tamoxifen, and toremifen are to be considered a non-clinical anatomical site tumors.

Low dose chemotherapy with methotrexate and inblastine/vinorelbine can cause regression or stabilization of disease in many patients.

Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression free survival and induced durable responses: The progression free survival rate was 81% at two years vs, 36% in the placebo group (Gounder MM).

Leave a Reply

Your email address will not be published. Required fields are marked *